Jump to content
CJC-Ipa Research

Published record

CJC-1295 Ipamorelin references

The original papers and reviews, with their study populations retained.

Read the experimental setups

Opening papers

For receptor amplification, start with Cunha and Mayo’s engineered-cell experiment. For sustained human hormone changes, open the healthy-adult CJC-1295 study. For class-level safety, read Sigalos and Pastuszak’s review.

The list also includes related compounds and earlier GHRH work. Their presence records the background to the pairing. No entry reports a controlled clinical trial of the fixed CJC-1295 Ipamorelin blend. The research bulletin follows the changes in experimental setting.

  1. Teichman SL, Ferris L, Mooradian AD, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. (Human; healthy adults) ↗
  2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. (Animal; rat pituitary cells and conscious swine) ↗
  3. Bowers CY, Reynolds GA, Durham D, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-982. (Human; 18 normal men) ↗
  4. Cunha SR, Mayo KE. Ghrelin and growth hormone (GH) secretagogues potentiate GH-releasing hormone (GHRH)-induced cyclic adenosine 3',5'-monophosphate production in cells expressing transfected GHRH and GH secretagogue receptors. Endocrinology. 2002;143(12):4570-4582. (In vitro; transfected HeLa cells) ↗
  5. Jetté L, Léger R, Thibaudeau K, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. (Animal; Sprague-Dawley rats) ↗
  6. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. (Human; review of multiple trials) ↗
  7. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026;20(1):2-12. (Human; meta-analysis of 5 RCTs) ↗
  8. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. (Human; healthy men 20-40 yr) ↗
  9. Stanley TL, Chen CY, Branch KL, et al. Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men. J Clin Endocrinol Metab. 2011;96(1):150-158. (Human; 13 healthy men) ↗
  10. Chapman IM, Bach MA, Van Cauter E, et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab. 1996;81(12):4249-4257. (Human; 32 healthy elderly subjects) ↗
  11. Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. (Human; healthy young men) ↗
  12. Cappola AR, Auchus RJ, El-Hajj Fuleihan G, et al. Hormones and Aging: An Endocrine Society Scientific Statement. J Clin Endocrinol Metab. 2023;108(8):1835-1874. (Human; scientific statement) ↗
  13. Growth hormone-releasing factor-sensitive adenylate cyclase system of purified somatotrophs. 1989. (In vitro; ovine pituitary somatotrophs) ↗
  14. Frohman LA, Downs TR, Heimer EP, Felix AM. Dipeptidylpeptidase IV and trypsin-like enzymatic degradation of human growth hormone-releasing hormone in plasma. J Clin Invest. 1989;83(5):1533-1540. (In vitro; human plasma) ↗
  15. Pharmacokinetics of growth hormone releasing factor [GRF(1-29)NH2] in normal men. 1986. (Human; healthy men) ↗